Spots Global Cancer Trial Database for secondary aml
Every month we try and update this database with for secondary aml cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
| Study title | NCT ID | Conditions | Interventions | Eligibility | Organization | Link |
|---|---|---|---|---|---|---|
| Safety Study of AG-120 or AG-221 in Combination With Induction and Consolidation Therapy in Participants With Newly Diagnosed Acute Myeloid Leukemia (AML) With an IDH1 and/or IDH2 Mutation | NCT02632708 | Newly Diagnosed... Untreated AML AML Arising Fro... AML Arising Fro... AML Arising Aft... | AG-120 AG-221 cytarabine daunorubicin idarubicin mitoxantrone etoposide | 18 Years - | Servier | |
| Haploidentical Stem Cell Transplant for Treatment Refractory Hematological Malignancies | NCT00145613 | Acute Lymphobla... Acute Myeloid L... Secondary AML Myelodysplastic... Secondary MDS Chronic Myeloid... Juvenile Myelom... Paroxysmal Noct... Lymphoma, Non-H... Hodgkin Disease | Stem Cell Trans... Miltenyi Biotec... Systemic chemot... | 2 Years - 21 Years | St. Jude Children's Research Hospital | |
| CPX-351+GO in Subjects 55 Years Old, or Older, With AML | NCT03878927 | Acute Myeloid L... | CPX-351 Gemtuzumab Ozog... | 55 Years - | Weill Medical College of Cornell University | |
| Safety Study of AG-120 or AG-221 in Combination With Induction and Consolidation Therapy in Participants With Newly Diagnosed Acute Myeloid Leukemia (AML) With an IDH1 and/or IDH2 Mutation | NCT02632708 | Newly Diagnosed... Untreated AML AML Arising Fro... AML Arising Fro... AML Arising Aft... | AG-120 AG-221 cytarabine daunorubicin idarubicin mitoxantrone etoposide | 18 Years - | Servier | |
| Phase III Study of CPX-351 Versus 7+3 in Patients 60-75 Years Old With Untreated High Risk (Secondary) Acute Myeloid Leukemia | NCT01696084 | High Risk Acute... | CPX-351 7+3 (cytarabine... | 60 Years - 75 Years | Jazz Pharmaceuticals | |
| Haploidentical Stem Cell Transplant for Treatment Refractory Hematological Malignancies | NCT00145613 | Acute Lymphobla... Acute Myeloid L... Secondary AML Myelodysplastic... Secondary MDS Chronic Myeloid... Juvenile Myelom... Paroxysmal Noct... Lymphoma, Non-H... Hodgkin Disease | Stem Cell Trans... Miltenyi Biotec... Systemic chemot... | 2 Years - 21 Years | St. Jude Children's Research Hospital | |
| Clinical Trial to Assess the Efficacy and Toxicity of Induction and Consolidation With CPX-351 for Patients Aged 60 to 75 Years With Secondary or High-risk Acute Myeloid Leukemia | NCT04230239 | Newly Diagnosed... | CPX-351 | 60 Years - 75 Years | PETHEMA Foundation | |
| Clinical Trial to Assess the Efficacy and Toxicity of Induction and Consolidation With CPX-351 for Patients Aged 60 to 75 Years With Secondary or High-risk Acute Myeloid Leukemia | NCT04230239 | Newly Diagnosed... | CPX-351 | 60 Years - 75 Years | PETHEMA Foundation | |
| EAP of CPX-351 (VYXEOS) for Patients 60-75 Years of Age With Secondary AML | NCT02533115 | Secondary AML | CPX-351 | 60 Years - 75 Years | Jazz Pharmaceuticals | |
| Clinical Trial to Assess the Efficacy and Toxicity of Induction and Consolidation With CPX-351 for Patients Aged 60 to 75 Years With Secondary or High-risk Acute Myeloid Leukemia | NCT04230239 | Newly Diagnosed... | CPX-351 | 60 Years - 75 Years | PETHEMA Foundation |
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
